quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:02:41·104d
ANALYSTRating
BridgeBio Oncology Therapeutics Inc. logo

Raymond James initiated coverage on BridgeBio Oncology Therapeutics with a new price target

BBOT· BridgeBio Oncology Therapeutics Inc.
Health Care
Original source

Companies

  • BBOT
    BridgeBio Oncology Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 11UpdateStifel$23.00
  • Jan 9UpdateRaymond James$24.00
  • Dec 5UpdateMorgan Stanley$20.00
  • Sep 17UpdateLeerink Partners$25.00
  • Sep 15UpdateH.C. Wainwright$27.00
  • Aug 15UpdatePiper Sandler$21.00

Related

  • PR1d
    BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
  • PR1d
    BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
  • PR2d
    BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
  • PR3d
    BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
  • PR10d
    BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
  • INSIDER28d
    SEC Form 4 filed by Lebowitz Peter F
  • INSIDER28d
    SEC Form 3 filed by new insider Lebowitz Peter F
  • SEC28d
    SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022